Clinical Trial Update: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL [Phase 1]

View source ↗

Summary

Phase 1 trial results for FT596 CAR-T cells with Rituximab as relapse prevention after autologous HSCT in non-Hodgkin lymphoma were posted, including disease ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• FT596
• Rituximab (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: NHL, Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2024-07-09